Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Other financing activities: 2009-2022

Historic Other financing activities for Cumberland Pharmaceuticals (CPIX) over the last 10 years, with Mar 2022 value amounting to -$370,464.

  • Cumberland Pharmaceuticals' Other financing activities fell 232.30% to -$370,464 in Q1 2022 from the same period last year, while for Mar 2022 it was -$650,484, marking a year-over-year decrease of 409.86%. This contributed to the annual value of $135,405 for FY2020, which is 86.46% down from last year.
  • Per Cumberland Pharmaceuticals' latest filing, its Other financing activities stood at -$370,464 for Q1 2022, which was up 41.44% from -$632,646 recorded in Q4 2021.
  • In the past 5 years, Cumberland Pharmaceuticals' Other financing activities ranged from a high of $1.0 million in Q3 2019 and a low of -$670,985 during Q4 2020.
  • Its 3-year average for Other financing activities is -$26,118, with a median of $102,565 in 2020.
  • In the last 5 years, Cumberland Pharmaceuticals' Other financing activities plummeted by 310.72% in 2020 and then skyrocketed by 181.39% in 2021.
  • Over the past 5 years, Cumberland Pharmaceuticals' Other financing activities (Quarterly) stood at $135,202 in 2018, then spiked by 135.52% to $318,423 in 2019, then tumbled by 310.72% to -$670,985 in 2020, then grew by 5.71% to -$632,646 in 2021, then plummeted by 232.30% to -$370,464 in 2022.
  • Its last three reported values are -$370,464 in Q1 2022, -$632,646 for Q4 2021, and $452,536 during Q3 2021.